BMG Pharma S.r.l, a specialty pharmaceutical company, has signed an exclusive distribution agreement with Ferrer InternacionaL S.A. (Ferrer), an R&D-based pharmaceutical company, granting them the rights to promote, sell and market its own product GelX for the Middle East, Eastern Europe, Russia and North Africa.

The launch of GelX will allow patients to receive the best care possible by using our innovative delivery technology to eliminate swallowing issues and discomfort associated with chemotherapy, radiotherapy, and related pharmacologic therapies.

"BMG's team are the inventors and generators of some of the major Rx devices in cancer palliative care and we are sure we are providing the market with a new generation of support for cancer patients," says Marco Mastrodonato, CEO of BMG.

"We are very pleased to be working with BMG on the launch of GelX in these territories," says Antonio Villaró, COO of Ferrer. "We have been impressed by the innovation and efficacy of the GelX delivery technology and look forward to providing significant improvements in the ease of use and compliance in patients with oral mucositis."

BMG granted the right of distribution to Ferrer for GelX in two different formulations: GelX Rinse 300 ml and GelX spray 100 ml.

Mucositis and stomatitis are inflammation of the oral cavity, normally accompanied by erythematous lesions and sometimes by ulcerative lesions that are particularly painful, making chewing and swallowing difficult.

GelX Rinse and GelX Spray have a mechanical action indicated for the management of pain by adhering to the mucosal surface of the mouth, soothing the lesions caused by chemotherapy and/or radiation therapy.  They can also be used as a preventive treatment before chemotherapy and/or radiation therapy to protect the oral mucosa.

GelX, in both formulations, is designed to benefit patients by improving the convenience, efficacy and compliance over existing marketed products.

Founded in 1959, Ferrer is a privately-held R&D-based pharmaceutical company headquartered in Barcelona. It is active in the pharmaceutical, health, fine chemicals and food sectors in Europe, Latin America, Africa, the Middle East, Asia and the United States.

BMG  is a specialty pharmaceutical company with head office in Milan, Italy, leveraging its proprietary technology to develop products that address unmet needs of patients.